Nasal delivery of encapsulated recombinant ACE2 as a prophylactic drug for SARS-CoV-2
Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved..
Angiotensin-converting enzyme 2 (ACE2) is responsible for cell fusion with SARS-CoV viruses. ACE2 is contained in different areas of the human body, including the nasal cavity, which is considered the main entrance for different types of airborne viruses. We took advantage of the roles of ACE2 and the nasal cavity in SARS-CoV-2 replication and transmission to develop a nasal dry powder. Recombinant ACE2 (rhACE2), after a proper encapsulation achieved via spray freeze drying, shows a binding efficiency with spike proteins of SARS-CoV-2 higher than 77 % at quantities lower than 5 µg/ml. Once delivered to the nose, encapsulated rhACE2 led to viability and permeability of RPMI 2650 cells of at least 90.20 ± 0.67 % and 47.96 ± 4.46 %, respectively, for concentrations lower than 1 mg/ml. These results were validated using nasal dry powder containing rhACE2 to prevent or treat infections derived from SARS-CoV-2.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:655 |
|---|---|
| Enthalten in: |
International journal of pharmaceutics - 655(2024) vom: 25. Apr., Seite 124009 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Baldelli, Alberto [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Angiotensin-Converting Enzyme 2 |
|---|
| Anmerkungen: |
Date Completed 15.04.2024 Date Revised 18.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijpharm.2024.124009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369835271 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369835271 | ||
| 003 | DE-627 | ||
| 005 | 20240418232801.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240318s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijpharm.2024.124009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1379.xml |
| 035 | |a (DE-627)NLM369835271 | ||
| 035 | |a (NLM)38493838 | ||
| 035 | |a (PII)S0378-5173(24)00243-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Baldelli, Alberto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nasal delivery of encapsulated recombinant ACE2 as a prophylactic drug for SARS-CoV-2 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2024 | ||
| 500 | |a Date Revised 18.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Angiotensin-converting enzyme 2 (ACE2) is responsible for cell fusion with SARS-CoV viruses. ACE2 is contained in different areas of the human body, including the nasal cavity, which is considered the main entrance for different types of airborne viruses. We took advantage of the roles of ACE2 and the nasal cavity in SARS-CoV-2 replication and transmission to develop a nasal dry powder. Recombinant ACE2 (rhACE2), after a proper encapsulation achieved via spray freeze drying, shows a binding efficiency with spike proteins of SARS-CoV-2 higher than 77 % at quantities lower than 5 µg/ml. Once delivered to the nose, encapsulated rhACE2 led to viability and permeability of RPMI 2650 cells of at least 90.20 ± 0.67 % and 47.96 ± 4.46 %, respectively, for concentrations lower than 1 mg/ml. These results were validated using nasal dry powder containing rhACE2 to prevent or treat infections derived from SARS-CoV-2 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Nasal drug delivery | |
| 650 | 4 | |a Nasal epithelium | |
| 650 | 4 | |a Recombinant ACE2 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Spray freeze drying | |
| 650 | 7 | |a Angiotensin-Converting Enzyme 2 |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 650 | 7 | |a Powders |2 NLM | |
| 700 | 1 | |a Jerry Wong, Chun Yuen |e verfasserin |4 aut | |
| 700 | 1 | |a Oguzlu, Hale |e verfasserin |4 aut | |
| 700 | 1 | |a Gholizadeh, Hanieh |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Yigong |e verfasserin |4 aut | |
| 700 | 1 | |a Ong, Hui Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Anika |e verfasserin |4 aut | |
| 700 | 1 | |a Traini, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Pratap-Singh, Anubhav |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of pharmaceutics |d 1992 |g 655(2024) vom: 25. Apr., Seite 124009 |w (DE-627)NLM07779785X |x 1873-3476 |7 nnns |
| 773 | 1 | 8 | |g volume:655 |g year:2024 |g day:25 |g month:04 |g pages:124009 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijpharm.2024.124009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 655 |j 2024 |b 25 |c 04 |h 124009 | ||